Prognostic value and therapeutic efficacy of interstitial circulating tumor cells in patients with advanced gastric cancer

Table 1 Relationship between interstitial circulating tumor cells and clinicopathological characteristics of patients with advanced gastric cancer, n (%)

Clinicopathological features	I-CTCs negative (n = 26)	I-CTCs positive (n = 33)	χ2	P value
Gender
Male	20 (43.5)	26 (56.5)
Female	6 (46.2)	7 (53.8)	0.029	0.864
Age, years
< 60	18 (52.9)	16 (47.1)
≥ 60	8 (32)	17 (68.0)	2.563	0.109
TNM staging
II	16 (53.3)	14 (46.7)
III	10 (34.5)	19 (65.5)	2.126	0.145
Infiltration depth
T1-T2	10 (58.8)	7 (41.2)
T3-T4	16 (38.1)	26 (61.9)	2.110	0.146
Lymph node metastasis
N0-N1	17 (54.8)	14 (45.2)
N2-N3	9 (32.1)	19 (67.9)	3.075	0.080
Degree of differentiation
Well	19 (59.4)	13 (40.6)
Poor	7 (25.9)	20 (74.1)	6.647	0.010
CEA
< 5	23 (47.9)	25 (52.1)
≥ 5	3 (27.3)	8 (72.7)	1.547	0.214
CA125
< 35	22 (42.3)	30 (57.7)
≥ 35	4 (57.1)	3 (42.9)	0.551	0.458
CA19-9
< 37	20 (41.7)	28 (58.3)
≥ 37	6 (54.5)	5 (45.5)	0.602	0.438
CA72-4
< 10	21 (41.2)	30 (58.8)
≥ 10	5 (62.5)	3 (37.5)	1.276	0.259

I-CTCs: Interstitial circulating tumor cells; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.